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Covid-19 has caused hundred of thousands of deaths and an economic damage amounting to
trillions of dollars, creating a desire for the rapid development of vaccine. Once available, vaccine
is gradually produced, evoking the question on how to distribute it best. While official vaccina-
tion guidelines largely focus on the question to whom vaccines should be provided first (e.g. to
risk groups), here we propose a generic strategy for their distribution in time and space, which
sequentially prioritizes regions with a high local infection growth rate. To demonstrate this strat-
egy, we develop an agent-based model describing the time-evolution of infection patterns and their
response to vaccination. For heterogeneous infection patterns, the proposed strategy at least halves
the number of deaths in our simulations compared to the standard practice of distributing vaccines
proportionally to the population density. This applies for a wide range of reproduction numbers and
vaccine production rates and might stimulate discussions on the importance of the spatiotemporal
distribution of vaccines for official guidelines.
Introduction The Covid-19 pandemic 2019/2020 [1–
5] has led to more than 3 million infections and 200.000
deaths worldwide (early May 2020) [6, 7] and an unprece-
dented social and economic cost which comprises a sud-
den rise of the unemployment rate by about 30 million in
the USA alone, and a damage of trillions of dollars at the
stock market and in the worldwide real economy. This
situation challenges politicians to decide on suitable mea-
sures and researchers to explore their efficiency, based on
models allowing to forecast and compare the evolution
of infectious diseases (like Covid-19) when taking one or
the other action.
Available measures to efficiently deal with epidemic
outbreaks at low infection numbers include a rigorous
contact-tracing (e.g. based on “Corona-Apps” [8]) and
-testing combined with quarantine of infected individu-
als [9–12]. Strict travel restrictions preventing an infec-
tious disease from entering disease-free regions (or to die
out locally [13]) present an alternative measure [14, 15],
whereas travel reductions by less than ∼ 99% [16] slow
down the spreading of the disease only slightly [16–18].
At higher infection numbers reducing the contact rate
through measures broadly affecting a population’s every-
day life, such as social distancing [10, 12, 19–22] and lock-
down [12, 23], remains as the only possibility to avoid
an explosion of infection numbers. Unless a population
persistently reduces the contact rate to the point where
infection numbers decrease (this requires a contact re-
duction by > 60% for a basic reproduction number of
R0 = 2.5 [21]), at such stages it has to accept that the
majority of its members has to endure the disease – until
finally reaching herd immunity [24].
The main hope which remains at such stages rests on
∗hlowen@hhu.de
†liebchen@fkp.tu-darmstadt.de
the rapid discovery and admission of vaccine [25] to ac-
celerate reaching herd immunity. However, while every
day where an infectious disease like Covid-19 is active
may cause thousands of additional deaths, even after ad-
mission, it may take months until sufficient vaccine is
available to overcome an infectious disease. Therefore it
is important to strategically distribute the available vac-
cines such that the number of deaths remains as small
as possible. Surprisingly, both official vaccination guide-
lines, e.g. for pandemic influenza [26, 27], and previous
works on vaccine distribution [28–30], focus on the ques-
tion to whom vaccine should be mainly provided, e.g.
to prioritize individuals by age or disease risk, and leave
the quest for a suitable spatial and temporal vaccine dis-
tribution aside. This results in the common practice of
simply distributing vaccines proportionally to the popu-
lation density [31].
In the present work we propose an alternative strategy
for the spatiotemporal distribution of gradually produced
vaccines, which hinges on the idea that the number of
deaths due to a spreading infectious disease is controlled
by the pattern of local infection rates, not by popula-
tion density. This strategy, which we call the ”focus-
ing strategy“, sequentially prioritizes regions (cities) with
the highest growth rates of the local infection numbers
(see Fig. 1 and the supplementary movie) and provides,
or ”focuses“, all available vaccines to those regions. To
compare the focusing strategy with the standard “de-
mographic” vaccine distribution practice, we develop an
agent-based model describing the time-evolution of an
epidemic outbreak (such as Covid-19) and its response to
vaccination. As our central result, we find that the num-
ber of deaths resulting from infections occurring after the
onset of vaccine production is generally smaller when fol-
lowing the focusing strategy rather than the demographic
distribution practice. In fact, for heterogeneous infection
patterns, the focusing strategy reduces the number of
deaths by more than a factor of two, for a large range of
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FIG. 1: Schematic illustration of the proposed spatiotemporal vaccine distribution strategies and of the simulation model. a)
shows the standard “demographic strategy”, where vaccines (dosage needles) are continuously distributed among all regions
(e.g. cities) proportionally to their population density (dots represent groups of individuals). b) shows the “infection weighted”
strategy, where vaccines are distributed proportionally to the local infection rates (red and orange dots) and c) shows the
”focusing strategy“ where at early times (clocks) only the region with the largest infection rate receives vaccines until the
growth rate of a second region catches up and also receives vaccines. d) shows a typical simulation snapshot for a city size
distribution following Zipf’s law taken 42 days after the onset of vaccination when following the focusing strategy. The legend
below a)-c) shows the states in our model.
basic reproduction numbers R0 and vaccine production
rates. The difference is largest for R0 ∼ 2− 3, as typical
for Covid-19, but even for R0 ∼ 1 and in the presence
of additional social distancing rules the focusing strategy
significantly increases the survival probability.
To explore the impact of the spatiotemporal vaccine
distribution on the disease-evolution in detail, we now
introduce a computational model. This model describes
the dynamics of N agents moving randomly in continu-
ous space in a box of size L × L with periodic bound-
ary conditions. The agents represent groups of individu-
als and have an internal state variable, which is inspired
by the SIR model [32–34] and its variants [35–38]. We
use colors (see legend in Fig. 1) to represent the possible
states in our simulations, which refer to individuals which
are “susceptible” (grey), “infected with weak symptoms”
(orange), “infected with significant symptoms” (red),
“recovered” (green) and “vaccinated” (blue). Infected
agents (orange and red) have an inner clock; they re-
main symptom free for a latency time tL and then show
mild (orange) or significant (red) symptoms for a dura-
tion tD− tL. After an overall disease duration of tD they
either recover with a survival probability so,r (green) or
die with probability 1 − so,r (black), where the indices
refer to agents with mild (orange) and significant symp-
toms (red), respectively. To model the infection dynam-
ics we describe the spatial motion of an agent with po-
sition ri(t) using Brownian dynamics r˙i(t) =
√
2Dηi(t),
where D is the diffusion coefficient controlling how fast
agents move and ηi(t) represents Gaussian white noise
with zero mean and unit variance. We assume that all
infected agents (orange and red) are infectious, both in
the latent phase and afterwards (as for Covid-19) and in-
fect a fraction of βo+βr of those susceptible agents (grey)
which are closer than a distance Rc; here, indices refer
to mild (orange) and significant (red) symptoms. Agents
showing significant symptoms (red) do not move but can
infect “visitors” if actively approaching them.
We now perform Brownian dynamics simulations [39–
44] starting with 2× 10−3N randomly distributed initial
infections and an initial reproduction number R0 = 2.5
such that infection numbers exponentially increase over
time. Let us assume that vaccine production starts af-
ter some initial transient and then allows to transfer ν
individuals per day from the susceptible to the immune
state. (Note that the duration of the initial transient is
unimportant in our simulations, if vaccination starts long
before herd immunity is reached.) Now considering the
time-evolution of the percentage of infected, dead and re-
covered individuals of a given population, and distribut-
ing the available vaccines proportionally to the popula-
tion density (bronze curves in Fig. 2), we observe an in-
fection maximum (panel a) about 30 days (two infection
cycles) after the onset of vaccine production, i.e. when
about 22% of the population have received vaccines and
2% of the population is infected. When distributing the
available vaccines proportionally to the local infection
rate (“infection weighted strategy”) instead, notably, the
infection maximum occurs an entire infection cycle ear-
lier (silver curve in panel a). Here the infection number
peaks when only 11% of the population has received vac-
cines and only 1% is infected. However, the infection
weighted strategy is not optimal but can be further im-
proved by exclusively providing all available vaccines to
the region (e.g. a city) with the highest infection rate
(“focusing strategy”). This means that initially only a
single region receives vaccines until the infection rate of a
second region catches up and both regions simultaneously
receive vaccines, until a third region catches up and so
on. Following this “focusing strategy” the infection peak
further shifts to earlier times (golden curve in panel a)
and occurs when only 0.6% of the population is infected.
Importantly, the resulting fraction of deaths reduces by
more than a factor of two when following the infection
weighted strategy (silver) rather than the demographic
strategy (bronze). It almost halves again when follow-
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FIG. 2: Competition of spatiotemporal vaccine distribution strategies regarding the time evolution of the fraction of infected
individuals (a), the fraction of deaths (b), and of recoveries and vaccinations (c). Dashed red lines show simulation results
without vaccination and bronze, silver (or grey) and gold show results for the demographic vaccine distribution strategy, the
infection weighted strategy and the focusing strategy respectively. The blue line in panel c) shows the vaccinated fraction of the
population and vertical blue lines mark the onset of vaccination; the specific time of which is unimportant (see text). Panels
on the right show simulation snapshots taken 14 days after the onset of vaccine production; insets magnify extracts of these
snapshots. Parameters: Disease duration tD = 14days; latency time tL = tD/3, survival probability sr = 0.965, so = 0.99,
vaccination rate ν = 0.1N/tD and initial reproduction number R0 = 2.5. (The latter is based on D = 10
2R2c/tD, βo = 0.3,
βr = 0.1; see Methods); L = 500Rc; curves are averaged over 100 random initial ensembles with N = 6000.
ing the focusing strategy instead (gold). This shows that
the precise spatial and temporal order of vaccine dona-
tion controls the number of survivors from an infectious
disease. In the methods section we develop a continuum
theory complementing our agent based simulations and
confirming the importance of the spatiotemporal vaccine
distribution at very large scales.
To systematically explore the robustness of these find-
ings we now repeat our simulations for different vaccine
production rates and initial reproduction numbers. Fig.
3 shows that the resulting fraction of deaths, counted
once the disease is gone, is generally highest for the de-
mographic strategy (bronze) and lowest for the focusing
strategy (gold). Mathematically, this is because vacci-
nation is most efficient at locations where it maximally
reduces the infection growth rate, which holds true in-
dependently of the specific parameter regime. The dif-
ferences among the individual strategies is comparatively
large if vaccine is produced fast enough to allow vacci-
nating at least about 1% of the population per day and
at reproduction rates around R0 ∼ 2 − 3. The latter
value might be sensible for Covid-19. However, even for
slower vaccine production or for R0 ∼ 1 − 2 (as typical
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FIG. 3: Fraction of deaths as a function of the vaccine pro-
duction rate (left) and the initial basic reproduction number
(right) for the demographic strategy (bronze), the infection-
weighted strategy (silver) and the focusing strategy (gold).
Results without vaccination (black) are shown for compari-
son. Remaining parameters as in Fig. 2.
for influenza), several percent of deaths can be avoided in
our simulations by strategically distributing the available
vaccines in space and time.
To further explore the applicability-regime of the fo-
cusing strategy, we now combine it with social distancing
rules, which reduce the reproduction number to R ∼ 1.
4We implement the latter as a repulsive three-body inter-
action among the agents (see Methods for details) which
prevents them from aggregating in groups of more than
two individuals. Also here, the resulting deaths frac-
tion (Fig. 4a) saturates significantly earlier when follow-
ing the focusing strategy (gold) rather than the demo-
graphic strategy (bronze). The difference in deaths num-
bers among the three different vaccination strategies is
almost identical to our corresponding results at R ∼ 1
but without social distancing (Fig. 3b).
Finally, we explore a possible impact of a nonuniform
population distribution (city structure) on the proposed
vaccination strategies. We create a population with a
spatial density distribution following Zipf’s law which
closely describes the city size distribution in most coun-
tries [45] as P˜c(s > S) ∝ 1/S, where P˜c(s) is the proba-
bility that a city is larger than S. To generate a popu-
lation featuring a corresponding population distribution,
we add an external potential U to the equation of mo-
tion of the agents (see Methods for details). Follow-
ing statistical mechanics, the resulting population den-
sity follows Boltzmann’s law P (r) ∝ exp[−U(r)/(kT )]
where P (r) is the probability that an agent is at position
r and kT = γD is the effective thermal energy of the
agents, controlling how often agents leave a “city” (min-
imum of U). Now matching Boltzmann’s distribution
with Zipf’s law yields a construction rule for U (see Meth-
ods) to create a population pattern featuring a charac-
teristic city-size distribution. Our resulting simulations,
shown in Fig. 4b, and in the supplementary movie (for
N = 55.000 agents), demonstrate that the focusing strat-
egy and the infection weighted-strategy again halve the
number of deaths compared to the demographic strategy.
Here, the former two strategies are comparatively close
to each other regarding the number of resulting deaths,
which indicates that in strongly inhomogeneous popula-
tions a suitable spatial vaccine distribution rule might be
even more important than the precise temporal sequence
of vaccine donation.
Conclusions Our simulations suggest that a strategic
spatiotemporal distribution of gradually produced vac-
cines generically increases the number of survivors in on-
going epidemic disease. In particular, by sequentially
prioritizing spatial regions (cities) with the highest local
infection growth rates, the proposed “focusing strategy”
reduces the number of deaths by more than a factor of
two compared to the standard practice of distributing
vaccines demographically. Such a strong difference oc-
curs for a large range of initial reproduction numbers
(R0 ∼ 1.5− 4) and vaccine production rates and even in
combination with additional social distancing measures,
if the underlying infection pattern is sufficiently hetero-
geneous and vaccine production starts long before the
population reaches herd immunity. Our results might in-
spire a variety of disease-specific future modelling works
incorporating large-scale data analyses to further test
the proposed strategy. They might also serve as use-
ful background information for advising politicians and
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FIG. 4: Competition of spatiotemporal vaccination strategies
a) in the presence of social distancing which is activated after
14 days (black vertical line) and reduces the reproduction
number to R ≈ 1 and b) for a population density distribution
following Zipf’s law. Colors and parameters as in Fig. 2, but
in b) we have N = 12000, L = 700, R0 = 2.7 (which is
based on D = 103R2c/tD and βo = 0.05, βr = 0.017) and
ν = 0.05N/tD.
could excite discussions regarding the importance of the
spatiotemporal distribution of gradually produced vac-
cines for official vaccination guidelines.
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Simulation details:
To calculate the spatial dynamics of the agents in our
model, we solve Langevin equations r˙i(t) =
√
2Dηi(t)
with i = 1, .., N using Brownian dynamics simulations
involving a forward Euler time-stepping algorithm and a
time-step of dt = 0.0028 days which amounts to about 4
minutes. After each timestep we check for each infected
agent (red or orange) which susceptible agents (grey) are
closer than Rc. We then change the state of the latter
agents to an infected state with an infection rate of β˜o =
3β˜r = 0.0075/dt (Figs. 2-4a), corresponding to infections
with mild symptoms (orange) and significant symptoms
(red), respectively. These rates yield βo = 3βr = 0.3
for the corresponding fractions of contacts which lead to
infections.
City size structure:
To generate a population density distribution with a
structure which is typical for cities, we add an exter-
nal potential landscape U(r) to the Langevin equations
describing the dynamics of the agents, i.e. r˙i(t) =√
2Dη(t) − ∇riU(ri)/γ. Here γ is an effective “drag”
coefficient determining the strength of the response of
the agents to U . We now create U as a superposition of
Gaussians, U(r) =
∑
j ae
− (r−rj)
2
2σ2
j , each of which leads to
a population density maximum around rj , which repre-
sents the center of city j. Here a is the strength (am-
plitude) of the reduced potential which we choose as
a = Dγ/2 = kT/2 and σj defines the radius of city j,
which we choose randomly from a distribution P (R) =
1
R
1
ln(Rmax/Rmin)
where Rmin = 20Rc and Rmax = 80Rc
are the minimal and the maximal possible “city radius”
in the simulations underlying Fig. 4b. We randomly dis-
tribute the city centers rj within the simulation box.
Social distancing:
To model social distancing, we add repulsive excluded
volume interactions among the agents which prevent that
groups of more than two agents form. That is, we
choose U = 12
∑
k,l 6=k Vklνkl where the sums run over
all agents and where Vkl represents the Weeks-Chandler-
Anderson interaction potential among agents k, l, i.e.
Vkl = 4
[
( drkl )
12 − ( drkl )6
]
+  if rkl ≤ 21/6d and Vkl = 0
otherwise. Here rkl denotes the distance between agents
k and l and rcut = 2
1/6d represents a cutoff radius be-
yond which the interaction potential is zero;  controls
the strength of the potential and is chosen such that
/γ = D. In our simulations at each timestep we choose
νkl = 1 if at least one of the agent k and l has a “neigh-
bor” at a distance closer than d = 3Rc and otherwise
we choose νkl = 0. In addition, we add a weak pair
attraction of strength D/10 and range d = 3Rc to our
simulations to support the formation of pairs. That way,
agents can form pairs but there is a significantly reduced
probability that they form triplets or larger groups.
Relation of reproduction number to simulation
parameters:
Here we relate the reproduction number R, which is the
average number of infections caused by an infected agent,
with the microscopic parameters in our simulation. For
this purpose, let us first consider the area A(t) covered
by a Brownian agent with radius Rc and diffusion coeffi-
cient D over a time t. This area is known as the Wiener
sausage [46] and reads
A(t) = piR2c +
8R2c
pi
∫ ∞
0
1− e−
2Dy2t
2R2c
y3(J20 (y) + Y
2
0 (y))
dy , (1)
where J0(y) and Y0(y) are the 0-th Bessel functions of the
first and second kind. Now denoting the agent density of
susceptible agents with ρS , the average number of (possi-
bly infectious) contacts during a time τ is A(τ)ρS . Thus,
if agents are infectious over an overall time of tD and the
fraction of contacts which lead to infections with signif-
icant (mild) symptoms is βr (βo), we obtain the follow-
ing expression for the (spatially averaged) reproduction
number:
R(t) = A(tD)ρS(t)(βo + βr) . (2)
This expression links the reproduction number with the
microscopic simulation parameters and reveals that the
reproduction number at time t is proportional to the av-
erage density of susceptible agents at time t.
Continuum theory:
Here we formulate a continuum theory of our agent-based
model. Integrating this model, e.g. by using finite dif-
ference simulations allows us to test the spatiotemporal
vaccination strategies at the continuum level. This is par-
ticularly useful to study very large length and timescales.
The continuum description is based on equations of mo-
tion for continuous variables (fields) representing the
mean number density of susceptible agents S(r, t), ex-
posed agents E(r, t) (infected but not yet diseased), in-
fected agents which are free of symptoms (or have mild
symptoms) F (r, t), infected agents with symptoms I(r, t)
and recovered (immune) agents G(r, t):
S˙(r, t) = −β′(E + F + I)S/ρ0 +D∇2S −∇ · (Sf)− ν′
E˙(r, t) = β′(E + F + I)S/ρ0 − αE +D∇2E −∇ · (Ef)
F˙ (r, t) = αrE − δF +D∇2F −∇ · (F f)
I˙(r, t) = α(1− r)E − δI −∇ · (If)
G˙(r, t) = δ(F + I) +D∇2G−∇ · (Gf) + ν′
Note here that the exposed state explicitly shows up as
a dynamical variable at the continuum level, but only
implicitly in our agent-based simulations where infected
6agents have an inner clock and are in the latent phase
before showing (mild) symptoms. In the above equa-
tions, β′ is the infection rate, i.e. 1/β′ is the mean
time between infectious contacts; α = 1/tL is the rate
to switch from the exposed (latent) state to the infected
state, δ = 1/(tD − tL) is the recovery rate and ν′(r, t)
is the spatiotemporal vaccination rate which is linked to
the constant vaccination rate in the agent-based model
via ν =
∫
dr ν′(r, t). The number r is the ratio of in-
fections proceeding symptom free (or with mild symp-
toms) and ρ0 = N/L
2 is the mean agent density. Fi-
nally, D is the diffusion coefficient and f(r) = −∇rU/γ
is the reduced force due to the external potential which
we use to create a density profile mimicking a typi-
cal city size distribution. The overall density converges
to a Boltzmann distribution S + E + F + I + G =
Nexp[−U(r)/(kT )]/ ∫ exp[−U(r)/(kT )]dr, yielding the
conservation law
∫
(S + E + F + I + G) dr = N which
can be viewed as an expression of the conservation of the
overall number density (or the number of agents) in the
coarse of the dynamics. We have simulated this model us-
ing the finite difference method, starting with the initial
state E = F = G = 0 and S = 1− , I =  where (r, t)
represents a small perturbation of the unstable steady
state E = F = G = I = 0, S = 1 which represents the
population before the emergence of the disease. The re-
sults of these simulations confirm that the spatiotemporal
distribution of continously distributed vaccines plays an
important role; also here, the infection-weighted strategy
and the focusing strategy strongly increase the number of
survivors as compared to the demographic distribution.
Supplementary Movie: The movie shows the time-
evolution of the modeled infection pattern forN = 55.000
agents and its response to the proposed spatiotemporal
vaccine distribution strategies. Parameters are as in Fig.
4b and the population distribution in the movie follows
a typical city size structure (Zipf’s law).
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